Prognostic value of procalcitonin in respiratory tract infections across clinical settings

Critical Care

Volumn 19, Issue 1, 2015, Pages

  Kutz, Alexander ^a   Briel, Matthias ^b   Christ Crain, Mirjam ^c   Stolz, Daiana ^c   Bouadma, Lila ^d   Wolff, Michel ^d   Kristoffersen, Kristina B ^e   Wei, Long ^f   Burkhardt, Olaf ^g   Welte, Tobias ^g   Schroeder, Stefan ^h   Nobre, Vandack ⁱ   Tamm, Michael ^c   Bhatnagar, Neera ^j   Bucher, Heiner C ^b   Luyt, Charles Edouard ^k   Chastre, Jean ^k   Tubach, Florence ^d   Mueller, Beat ^a   Schuetz, Philipp ^a  

^a University Department of Medicine Kantonsspital Aarau   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^g HANNOVER MEDICAL SCHOOL   (Germany)

^h Duren Hospital   (Germany)

ⁱ FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^j MCMASTER UNIVERSITY   (Canada)

^k SORBONNE UNIVERSITÉ   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROCALCITONIN; BIOLOGICAL MARKER; CALCITONIN; PROTEIN PRECURSOR;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED CLINICAL TRIAL (TOPIC); EMERGENCY WARD; FEMALE; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); MORTALITY; PREDICTIVE VALUE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY TRACT INFECTION; SENSITIVITY ANALYSIS; TREATMENT FAILURE; ACUTE DISEASE; BLOOD; EMERGENCY HEALTH SERVICE; META ANALYSIS; MIDDLE AGED; RESPIRATORY TRACT INFECTIONS;

ACUTE DISEASE; AGED; BIOMARKERS; CALCITONIN; EMERGENCY SERVICE, HOSPITAL; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PRECURSORS; RESPIRATORY TRACT INFECTIONS; TREATMENT FAILURE;

EID: 84926344321     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-015-0792-1     Document Type: Article

References (24)

1. Warren HS. Strategies for the treatment of sepsis. N Engl J Med. 1997;336:952-3.
2. Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, et al. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med. 1990;113:227-42.
3. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589-96.
4. Masson S, Caironi P, Spanuth E, Thomae R, Panigada M, Sangiorgi G, et al. Presepsin (soluble CD14 subtype) and procalcitonin levels for mortality prediction in sepsis: data from the Albumin Italian Outcome Sepsis trial. Crit Care. 2014;18:R6.
5. Garnacho-Montero J, Huici-Moreno MJ, Gutiérrez-Pizarraya A, López I, Márquez-Vácaro JA, Macher H, et al. Prognostic and diagnostic value of eosinopenia, C-reactive protein, procalcitonin, and circulating cell-free DNA in critically ill patients admitted with suspicion of sepsis. Crit Care. 2014;18:R116.
6. Suberviola B, Castellanos-Ortega A, Ruiz Ruiz A, Lopez-Hoyos M, Santibañez M. Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission. Intensive Care Med. 2013;39:1945-52.
7. Schuetz P, Litke A, Albrich WC, Mueller B. Blood biomarkers for personalized treatment and patient management decisions in community-acquired pneumonia. Curr Opin Infect Dis. 2013;26:159-67.
8. Magrini L, Gagliano G, Travaglino F, Vetrone F, Marino R, Cardelli P, et al. Comparison between white blood cell count, procalcitonin and C reactive protein as diagnostic and prognostic biomarkers of infection or sepsis in patients presenting to emergency department. Clin Chem Lab Med. 2014;52:1465-72.
9. Li Z, Wang H, Liu J, Chen B, Li G. Serum soluble triggering receptor expressed on myeloid cells-1 and procalcitonin can reflect sepsis severity and predict prognosis: a prospective cohort study. Mediators Inflamm. 2014;2014:641039.
10. Zhao Y, Li C, Jia Y. Evaluation of the Mortality in Emergency Department Sepsis score combined with procalcitonin in septic patients. Am J Emerg Med. 2013;31:1086-91.
11. Pierrakos C, Vincent JL. Sepsis biomarkers: a review. Crit Care. 2010;14:R15.
12. Karlsson S, Heikkinen M, Pettilä V, Alila S, Väisänen S, Pulkki K, et al. the Finnsepsis Study Group. Predictive value of procalcitonin decrease in patients with severe sepsis: a prospective observational study. Crit Care. 2010;14:R205.
13. Georgopoulou AP, Savva A, Giamarellos-Bourboulis EJ, Georgitsi M, Raftogiannis M, Antonakos N, et al. Early changes of procalcitonin may advise about prognosis and appropriateness of antimicrobial therapy in sepsis. J Crit Care. 2011;26:331. e1-e7.
14. Haasper C, Kalmbach M, Dikos GD, Meller R, Müller C, Krettek C, et al. Prognostic value of procalcitonin (PCT) and/or interleukin-6 (IL-6) plasma levels after multiple trauma for the development of multi organ dysfunction syndrome (MODS) or sepsis. Technol Health Care. 2010;18:89-100.
15. Schuetz P, Briel M, Christ-Crain M, Stolz D, Bouadma L, Wolff M, et al. Procalcitonin to guide initiation and duration of antibiotic treatment in acute respiratory infections: an individual patient data meta-analysis. Clin Infect Dis. 2012;55:651-62.
16. Schuetz P, Müller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2012;9:CD007498. doi:10.1002/14651858.CD007498.pub2.
17. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44:S27-72.
18. Schuetz P, Aujesky D, Muller C, Muller B. Biomarker-guided personalised emergency medicine for all - hope for another hype? Swiss Med Wkly. 2015;145:w14079.
19. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med. 2001;163:1730-54.
20. Woodhead M, Blasi F, Ewig S, Huchon G, Leven M, Ortqvist A, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005;26:1138-80.
21. Schuetz P, Koller M, Christ-Crain M, Steyerberg E, Stolz D, Müller C, et al. Predicting mortality with pneumonia severity scores: importance of model recalibration to local settings. Epidemiol Infect. 2008;136:1628-37.
22. Huang D, Weissfeld L, Kellum J, Yealy D, Kong L, Martino M, et al. Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med. 2008;52:48-58. e2.
23. Schuetz P, Suter-Widmer I, Chaudri A, Christ-Crain M, Zimmerli W, Mueller B, et al. Prognostic value of procalcitonin in community-acquired pneumonia. Eur Respir J. 2011;37:384-92.
24. Krüger S, Ewig S, Kunde J, Hartmann O, Marre R, Suttorp N, et al. the CAPNETZ study group. Assessment of inflammatory markers in patients with community-acquired pneumonia-influence of antimicrobial pre-treatment: results from the German competence network CAPNETZ. Clin Chim Acta. 2010;411:1929-34.